Our Pipeline

Reata’s development programs continue to yield a robust pipeline of clinical-stage drug candidates for a broad array of indications with significant unmet need.

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Pivotal Programs
Pivotal Programs
Alport Syndrome Bard
Friedreich’s Ataxia Omav
CTD-PAH Bard
See Full Pipeline

Ongoing Clinical Trial Websites

For Patients With Alport Syndrome
For Patients with friedreich's ataxia
For Patients with PAH with Scleroderma. Lupus, and Connective Tissue Disease